Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
The companies have launched a center that offers consulting and management specifically for genomically targeted or precision medicine trials.
The companies are creating a new center that will offer support services to biopharmaceutical companies, CROs, and others in designing genetically informed clinical trials.
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
The companies are working together to help insurers reduce wasteful spending and spur use of medically necessary tests.
Cigna worked with InformedDNA to come up with scenarios under which it would cover whole-exome sequencing, although it still considers whole-genome analysis investigational.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.